Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have received an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $256.00.

Several equities analysts recently issued reports on the stock. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $10.94 on Friday. Gossamer Bio has a 52 week low of $9.10 and a 52 week high of $309.60. The firm’s fifty day moving average is $12.97 and its 200-day moving average is $19.47. The firm has a market cap of $66.84 million, a P/E ratio of -0.20 and a beta of 2.00.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LP boosted its holdings in shares of Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after buying an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after buying an additional 1,469,175 shares during the period. Bank of America Corp DE bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at $65,000. Hhlr Advisors LTD. bought a new stake in shares of Gossamer Bio in the 2nd quarter valued at $819,000. Finally, ARCH Venture Management LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter valued at $1,326,004. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.